Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis

BACKGROUND: Severe hypoglycemic events (SHEs) in patients with diabetes are associated with substantial health care costs in the United States (US). Injectable glucagon (IG) is currently available for treatment of severe hypoglycemia but is associated with frequent handling errors. Nasal glucagon (N...

Full description

Saved in:
Bibliographic Details
Published in:J Diabetes Sci Technol
Main Authors: Pöhlmann, Johannes, Mitchell, Beth D., Bajpai, Sanjay, Osumili, Beatrice, Valentine, William J.
Format: Artigo
Language:Inglês
Published: SAGE Publications 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6955465/
https://ncbi.nlm.nih.gov/pubmed/30700165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296819826577
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items